文献速递胸部肿瘤

联合分子与免疫血液检测在低剂量CT肺癌筛查中安全减少假阳性的临床价值

Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose Computed Tomography Lung Cancer Screening.
PubMed 文献 · J Thorac Oncol · 2026-02-16

BioMILD前瞻性研究纳入304例重度吸烟者,评估血浆microRNA检测(MSC)联合免疫特征分类器(ISC)对LDCT检出可疑结节的鉴别价值。联合模型灵敏度96%、阴性预测值98%(95%CI 0.93-0.99),较MSC单用NPV提升0.05(95%CI 0.01-0.08),假阳性减少37%。

要点

  • ISC与年龄(p=0.0323)和Lung-RADS(p=0.0008)相关,2年内确诊癌症者ISC显著更高(p=0.0006)。
  • 联合ISC与MSC模型灵敏度96%、NPV 98%(95%CI 0.93-0.99),假阳性减少37%。
  • 联合模型NPV较MSC单用提升0.05(95%CI 0.01-0.08),有助于排除恶性、减少不必要随访。

核心结论

  • 整合免疫与分子标志物可显著提高LDCT筛查准确性,联合模型高NPV有助于排除LDCT检出结节的恶性。

研究设计与样本

  • BioMILD前瞻性多中心意大利肺癌筛查试验,纳入304例重度吸烟者,中位随访7.5年。
  • 血浆和外周血单核细胞样本前瞻性收集,MSC与ISC通过实时定量PCR检测。
  • 患者来源异种移植模型成瘤作为肿瘤侵袭性指标。

主要发现

  • ISC与年龄(p=0.0323)和Lung-RADS(p=0.0008)相关。
  • 2年内确诊癌症的患者ISC显著更高(p=0.0006)。
  • 较高ISC值与患者来源异种移植模型成功成瘤相关(p=0.0449)。
  • 联合ISC与MSC模型灵敏度96%、NPV 98%(95%CI 0.93-0.99)。
  • 联合模型较MSC单用NPV提升0.05(95%CI 0.01-0.08),假阳性减少37%。

关键数值与推荐

  • 联合ISC与MSC模型灵敏度96%、NPV 98%(95%CI 0.93-0.99)。
  • 联合模型较MSC单用ΔNPV=+0.05(95%CI 0.01-0.08),假阳性减少37%。

临床怎么用

  • 对LDCT检出可疑结节的重度吸烟者,联合ISC与MSC可提高排除恶性的信心。
  • 联合模型高NPV有助于减少不必要的随访检查和侵入性操作。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Low-dose computed tomography (LDCT) screening saves lives but is limited by high false-positive rates, necessitating noninvasive risk stratification. The prospective Bio-Multicentric Italian Lung Detection (BioMILD) trial was the first to validate the combination of a plasma microRNA test (MSC) with LDCT to personalize screening intervals. This study integrates a novel immune signature classifier (ISC), based on peripheral blood mononuclear cell profiling, to complement MSC, maximize information from a single blood draw, and further optimize the management of suspicious lung nodules. METHODS: Plasma and peripheral blood mononuclear cell samples were prospectively collected from 304 heavy smokers enrolled in the BioMILD trial who presented with LDCT-detected suspicious nodules and a 7.5-year median follow-up. MSC and ISC tests were determined by real-time quantitative polymerase chain reaction. Grafting of patient-derived xenograft models, obtained from the same patients, was used as indicator of tumor aggressiveness. RESULTS: ISC was associated with age (p = 0.0323) and Lung-RADS (p = 0.0008) and was significantly higher in patients with cancers diagnosed within 2 years (p = 0.0006). Higher ISC values also correlated with successful patient-derived xenograft engraftment (p = 0.0449). In terms of diagnostic performance, the combined ISC and MSC model achieved 96% sensitivity and 98% negative predictive value (NPV) (95% confidence interval: 0.93-0.99). It represented a significant enhancement than MSC alone (ΔNPV = +0.05; 95% confidence interval: 0.01-0.08) and resulted in a 37% reduction of false positives. CONCLUSION: Integration of immune and molecular markers significantly enhances LDCT screening accuracy. The higher NPV achieved by the combined model allows greater confidence in ruling out malignancy among LDCT-detected nodules, thereby reducing unnecessary follow-up examinations and invasive procedures.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Zanghì A, Moro M, Fortunato O, et al. Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose Computed Tomography Lung Cancer Screening. J Thorac Oncol. 2026. PMID: 41707946. doi:10.1016/j.jtho.2026.103614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。